1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : BIOTECH
  4. CLIMB BIO INC.
Climb Bio Inc.
XNAS: CLYM
755.8K
XNAS Volume

XNAS 07 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Climb Bio Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Climb Bio Inc quarterly results: revenue, profit, and P&L – 13 quarter history

  • NEUTRAL

    Quarterly Revenue Climb Bio Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

  • NEGATIVE

    Quarterly Net Profit Climb Bio Inc Jun-2026 Quarterly Net Profit is $-13 Million which is growth of -55.8% YoY.

Climb Bio Inc., Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
15.415.219.314.910.72310.911.756.435.156.7
Operating Profit
-15.4-15.2-19.3-14.9-10.7-23-10.9-11.7-56.4-3-5.1-5-6.7
1.91.5--2.22.3---1.31.41.3-
Profit Before Tax
-13.5-13.7-17.5-12.9-8.7-20.8-8.4-8.9-54.9-1.7-3.6-4-5.2
Tax
-------------
⌄
-13.5-13.7-17.5-12.9-8.7-20.8-8.4-8.9-54.9-1.7-3.6-4-5.2
Diluted NI Avail to Com Stockholders Ann.
-13.5-13.7-17.5-12.9-8.7-20.8-8.4-8.9-54.9-1.7-3.6-4-5.2
Basic EPS
-0.2-0.2-0.3-0.2-0.1-0.3-0.1-0.1-1.8-0.1-0.1-0.2-0.2
Diluted EPS After ExtraOrdinary
-0.2-0.2-0.3-0.2-0.1-0.3-0.1-0.1-1.8-0.1-0.1-0.1-0.2
Number Of Shares End
76.268.268.26867.667.567.46730.427.627.527.126.8
Net Income Continuing Discontinued Operations
-13.5-13.7-17.5-12.9-8.7-20.8-8.4-8.9-54.9-1.7-3.6-4-5.2
Normalized Income
-13.5-13.7-17.5-12.9-8.5-20.7-8.4-9-54.9-1.7-3.8-3.7-5.6
Interest Income
1.91.5--2.22.3---1.31.41.3-
Interest
-------------
Net Interest Income
1.91.5--2.22.3---1.31.41.3-
EBIT
-15.4-15.2-19.3-14.9-10.7-23-10.9-11.7-56.4-3-5.1-5-6.7
EBITDA
-15.3-15.2-19.3-14.9-10.7-23-10.9-11.7-56.4-3-5.1-5-6.7
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
0000---------
Profit From Continuing Operations
-13.5-13.7-17.5-12.9-8.7-20.8-8.4-8.9-54.9-1.7-3.6-4-5.2
Normalized EBITDA
-15.3-15.2-19.2-14.8-10.5-23-10.9-11.8-56.4-3-5.3-4.8-7.1
*All financials are in USD Million and price data in USD

Climb Bio Inc competitor comparison and performance snapshot within industry

Climb Bio Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

  • NEUTRAL

    Annual Revenue Climb Bio Inc Annual Revenue is $0 Million which is growth of 0% YoY.

  • POSITIVE

    Annual Net Profit Climb Bio Inc Annual Net Profit is $-60 Million which is growth of 19.0% YoY.

Climb Bio Inc., Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
-
-
 
Cost Of Rev. Ann.
-
-
 -------
Gross Profit Ann.
-
-
 -------
Operating Exp. Ann.
14.6%
41.9%
64.867.930.440.345.135.711.84.7
Operating Profit Ann.
-
-
-64.8-67.9-30.4-40.3-45.1-35.7-11.8-4.7
-
-
 8.38.14.6----
Other Exp. Ann.
-
-
 -0.3-51.70.5-0.1-11.8-8.9-1.9
PBT Ann.
-
-
-57.6-59.9-73.9-35.1-45.2-47.5-20.7-6.6
Tax Ann.
-
-
 -------
⌄
-
-
-57.6-59.9-73.9-35.1-45.2-52-23-7.4
Diluted NI Avail to Com Stockholders Ann.
-
-
-57.6-59.9-73.9-35.1-45.2-52-23-7.4
EPS Ann.
-
-
 -0.9-1.5-1.3-1.7-4.2-3.4-1.1
Diluted EPS Ann.
-
-
 -0.9-1.5-1.3-1.7-4.2-3.4-1.1
Number Of Shares End
37.2%
42.3%
 68.267.427.526.426.211.7-
Total Exp. Ann.
14.6%
41.9%
 67.930.440.345.135.711.84.7
Net Income Continuing Discontinued Operations Ann.
-
-
-57.6-59.9-73.9-35.1-45.2-47.5-20.7-6.6
Normalized Income Ann.
-
-
-57.5-59.6-22.2-35.7-43.8-47.3-11.8-3.8
Interest Income Ann.
-
-
 8.38.14.6----
Interest Ann.
-
-
 -------
EBITDA Ann.
-
-
-64.6-67.8-30.4-40.3-45.1-35.7-11.8-4.7
Reconciled Cost Of Rev. Ann.
-
-
 -------
Reconciled Depr. Ann.
-
-
0.10.1------
Profit From Continuing Operations Ann.
-
-
-57.6-59.9-73.9-35.1-45.2-47.5-20.7-6.6
Normalized EBITDA Ann.
-
-
-64.5-67.521.3-40.8-43.7-35.5-2.9-1.9
*All financials are in USD Million and price data in USD
Operating Exp. Ann.
1Y CHG
123.4%
2Y CAGR
29.8%
3Y CAGR
14.6%
5Y CAGR
41.9%

Climb Bio Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

  • NEGATIVE

    Total Shareholders Fund Climb Bio Inc Dec-2025 Total Shareholders Fund is $160 Million which is growth of -24.3% YoY.

  • NEGATIVE

    Total Assets Climb Bio Inc Dec-2025 Total Assets is $168 Million which is growth of -22.8% YoY.

Climb Bio Inc., Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
7.5%
46.8%
167.7217.2110.5135173.224.621.4
⌄
5%
18.7%
7.35.32.96.363.10.8
⌄
7.6%
-
160.5211.9107.6128.7167.2-25-5.6
Total Capitalization Ann.
7.6%
49.3%
160.5211.9107.6128.7167.221.620.6
Tangible Assets Ann.
7.6%
49.3%
160.5211.9107.6128.7167.221.620.6
Working Capital Ann.
-8.3%
39.2%
98.9149.9107.4128.3142.218.920.5
Invested Capital Ann.
7.6%
-
160.5211.9107.6128.7167.2-25-5.6
Tangible Book Value Ann.
7.6%
-
160.5211.9107.6128.7167.2-25-5.6
Borrowings Ann.
0%
-
0.50.50.40.5---
Net Debt Ann.
-
-
-------
Share Issued Ann.
21.6%
15.3%
47.867.327.726.626.223.523.5
Number Of Shares End
37.2%
42.3%
68.267.427.526.426.211.7-
*All financials are in USD Million and price data in USD
Total Assets Ann.
1Y CHG
-22.8%
2Y CAGR
23.2%
3Y CAGR
7.5%
5Y CAGR
46.8%
Total Current Liabilities Ann.
1Y CHG
42.9%
2Y CAGR
58.1%
3Y CAGR
4.7%
5Y CAGR
17.7%
Total ShareHolders Funds Ann.
1Y CHG
-24.3%
2Y CAGR
22.1%
3Y CAGR
7.6%

Climb Bio Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

  • POSITIVE

    Book Value Per Share Climb Bio Inc Book Value Per Share is $4 which is growth of 52.1% YoY.

  • NEUTRAL

    ROE Climb Bio Inc ROE is 0% which is growth of 0% YoY.

Climb Bio Inc., Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
RoA Ann. %
-
-
--45.11%-28.61%-29.36%-52.59%-99.74%-34.55%
ROE Ann. %
-
-
--46.26%-29.72%-30.58%-73.17%--
ROIC %
-
-
--3.9-4.6-5.9-6.1--
OPM Ann. %
-
-
-------
Inventory Turnover Ratio Ann.
-
-
-------
Asset Turnover Ann. %
-
-
-------
Working Capital Turnover Ann.
-
-
Quick Ratio Ann.
-
-
-30.838.421.323.76.727.1
Current Ratio Ann.
-
-
-31.438.92224.67.227.2
Interest Coverage Ratio Ann.
-
-
-------
LT Debt To Equity Ann.
-
-
----
*All financials are in USD Million and price data in USD

Climb Bio Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

  • NEGATIVE

    Cash From Operating Activity Climb Bio Inc Cash From Operating Activity is $-54 Million which is growth of -249.3% YoY.

  • NEGATIVE

    Net Cash Flow Climb Bio Inc Net Cash Flow is $-52 Million which is growth of -769.9% YoY.

Climb Bio Inc., Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
-
-
-54.4-15.6-20.6-37.4-36.1-14.1-5
-56.7%
-19.1%
2.8-121.16934.4-1158.1
-
-
-0130.70.8177.24.926.2
Cash Plus Cash Eqv. End Of Year Ann.
-6.4%
11.7%
35.787.293.143.646.920.521.2
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-
-51.5-5.949.2-2.926.2-1.121.2
Cash Plus Cash Eqv. Begin Of Year Ann.
23%
32.7%
87.293.143.646.920.521.2
Income Tax Paid Supplemental Data Ann.
-
-
-------
Interest Paid Supplemental Data Ann.
-
-
-------
Capex Ann.
-
-
-0.2------
Issuance Of Capital Stock Ann.
-12.2%
35.5%
119.8-177.14.926.2
Issuance Of Debt Ann.
-
-
-------
Repayment Of Debt Ann.
-
-
-------
Repurchase Of Capital Stock Ann.
-
-
-------
Free Cash Flow Ann.
-
-
-54.5-15.6-20.6-37.4-36.1-14.1-5
*All financials are in USD Million and price data in USD
Cash from Investing Act. Ann.
2Y CAGR
-79.9%
3Y CAGR
-56.7%
5Y CAGR
-19.1%